Brind.

Bristol Myers Squibb and SystImmune, Inc. announced a collaboration to jointly develop iza-bren, with data presentation scheduled at the WCLC Annual Meeting in Barcelona, Spain.

1 report, 1 independent Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bristol Myers Squibb and SystImmune, Inc. announced a collaboration to jointly develop iza-bren, with data presentation scheduled at the WCLC Annual Meeting in Barcelona, Spain.

Who's involved

What this event is mainly about
BarcelonaBristol-Myers SquibbSpain

How it developed

Newest first. Tap a step to see who reported it.
  1. Dr. Salter-Cid led teams at Bristol Myers Squibb on June 1, 2026.Sub-event
  2. Bristol Myers Squibb received FDA breakthrough therapy status for its drug iza-bren, advancing development outside of China licensing.Sub-event
  3. Collaboration between BMS and SystImmune on iza-bren announced for WCLC in Barcelona.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswireSystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025 Safety & efficacy of iza-bren, an EGFRxHER3 bispecific topoisomerase inhibi